Dataset opportunity
Shipmercury — 监管记录数据集机会
Shipmercury 持有的中等监管记录数据集，可用于监管 RAG 和合规 Copilots。
Score
69.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
58%
Action
收购
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球医药物流市场预计到 2026 年将达到 1195.6 亿美元，复合年增长率为 8.8%（2026-2034 年）。[1]
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- 📝Published article
冷链物流中的人工智能和实时监控
source ↗
Profile
Dataset profile
Type
监管记录数据集
Modality
文本
Sector
出行
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
混合所有权 — 许可权待明确
Buyer persona
RegTech & 合规 AI 供应商
Shipmercury 提供文本模态的监管记录数据集，该数据集由其专业的生物制药物流业务编译而成。数据包括业务记录、物联网遥测数据和监管协议知识库，非常适合开发监管 RAG 系统，以应对复杂的合规性和供应链查询。
该数据运营于全球制药物流市场，该市场预计在 2026 年将达到1195.6 亿美元，并以 8.8% 的复合年增长率扩张。[1] 虽然访问此有价值的数据集受GDP 合规性等医疗保健法规的约束，并且需要客户进行匿名化，但其稀有性和在高度增长、受监管的行业中直接应用于人工智能的机会，为买家提供了显著的机遇。⚠ 注意（有价值的数据，可协商访问）：物流遥测数据（GPS/温度）是专有的，但货物内容属于客户；受医疗保健物流法规（GDP 合规性）的约束；数据访问可能需要匿名化特定的生物制药客户身份。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Shipmercury 拥有详细说明制药运输复杂监管和物流现实的专有数据集。这些数据记录了全球制药物流市场的实际操作，该市场预计将超过 1190 亿美元，使其成为RegTech 和合规性人工智能供应商的高价值资产。它提供了为复杂的监管 RAG 模型提供支持所需的真实地面真相，其中包含海关文件、冷链处理和链条追踪协议的示例，提供了独特的竞争优势。
See dimension details ↓- ICP Audit92
✓ 良好目标 — Shipmercury 是一家专注于生命科学领域的专业物流公司，而非数据销售商；其运营运输和监管合规数据是有价值的、休眠的副产品，使其成为理想的目标。问题：最初的描述“监管记录数据集机会”具有误导性；该公司的核心业务显然是物流，而不是销售这些数据；公司规模估计因来源而异，从 71 到 126 名员工不等，但都属于合理的中小企业定义。[13, 12]
- Deep Qualification80
⚠ 需要审查 — Shipmercury 是一家专注于生命科学领域的专业物流提供商，作为副产品生成有价值的监管和遥测数据。虽然数据所有权是混合的，并且其隐私政策明确限制出售客户名单，但近期收购 King Courier 表明了战略增长，使得其聚合的、匿名的部分数据成为一个可行但复杂的机遇。[许可受限]
- Dataset Specificity78
主导的“监管”，行业 mobility，2 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity70
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume64
5 条证据
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于监管 RAG
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
人工智能买家需求旺盛，这得益于自动化合规和提高大型制药物流市场效率的关键需求，该市场正以强劲的 8.8% 复合年增长率扩张。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility28
受限/未知
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility30
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength77
4 种证据类型，5 条证据
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License36
所有权=混合，许可=权利不明确
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Knowledge base / docs
这些证据证实了包含生命科学客户国际运输的文本记录的存在，包括海关文件处理和商业药品处理流程。
IoT / sensor data
此样本证明了文本记录背后的运营背景，表明 Shipmercury 积极监控货物的温度控制，这是冷链合规的关键组成部分。
business_records
这些记录展示了管理生命科学物流的历史，进一步证明了在国内外服务渠道中持续的运营和主动跟踪。
Regulatory records
此文本明确证实该数据集包含有关管理生物制药供应链的信息，重点关注监管合规性和链条追踪可见性。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Shipmercury Regulatory Records — a Moderate regulatory records dataset (Text modality) in the mobility domain. Primary AI use-case: Regulatory RAG. Market signal: Global Pharmaceutical Logistics Market to reach $119.56 billion in 2026, growing at a CAGR of 8.8% (2026-2034). [1]. Investment score 69.1/100 (confidence 0.58). Recommended action: Acquire.
From the marketplace
Explore live data opportunities
011H — 监管记录数据集机会
View opportunity →工业Bcomp — 法规记录数据集机会
View opportunity →金融Deutsche Pensexpert — 监管记录数据集机会
View opportunity →